Drug Design—Past, Present, Future
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Drug design is a complex pharmaceutical science with a long history. Many achievements have been made in the field of drug design since the end of 19th century, when Emil Fisher suggested that the drug–receptor interaction resembles the key and lock interplay. Gradually, drug design has been transformed into a coherent and well-organized science with a solid theoretical background and practical applications. Now, drug design is the most advanced approach for drug discovery. It utilizes the innovations in science and technology and includes them in its wide-ranging arsenal of methods and tools in order to achieve the main goal: discovery of effective, specific, non-toxic, safe and well-tolerated drugs. Drug design is one of the most intensively developing modern sciences and its progress is accelerated by the implication of artificial intelligence. The present review aims to capture some of the most important milestones in the development of drug design, to outline some of the most used current methods and to sketch the future perspective according to the author’s point of view. Without pretending to cover fully the wide range of drug design topics, the review introduces the reader to the content of Molecules’ Special Issue “Drug Design—Science and Practice”.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
SwissDock, a protein-small molecule docking web service based on EADock DSS
Grosdidier, A., Zoete, V., & Michielin, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr366 · Cited by 1,950
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Fogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Machine learning in chemoinformatics and drug discovery
Lo, Y.-C., Rensi, S. E., Torng, W., & Altman, R. B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.010 · Cited by 960
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Functional genomic hypothesis generation and experimentation by a robot scientist
King, R. D., Whelan, K. E., Jones, F. M., Reiser, P. G. K., Bryant, C. H., Muggleton, S. H., Kell, D. B., & Oliver, S. G. (2004) · Nature · doi:10.1038/nature02236 · Cited by 662 · cited 1×
“Adam was constructed to run microbiological experiments, analyse the results itself, define hypotheses, design experiments to test these hypotheses and repeat this cycle until a validated hypothesis is derived [61].”
MethodMolecular representations in AI-driven drug discovery: a review and practical guide
David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00460-5 · Cited by 587 · cited 1×
“In order to be applied all these advanced technologies, the molecular structure should be encoded numerically [31].”
BackgroundPharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).
Prentis, R., Lis, Y., & Walker, Sr. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03318.x · Cited by 471 · cited 1×
“However, during the last 20 years many in silico tools and models have been developed to assess the physicochemical and ADME properties of drug candidates during the experimental stage and the attrition rate due to decreases in pharmacokinetics from 39% in the past [13] to the current negligible 1% [11].”
BackgroundUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378 · cited 2×
“[28] divided the whole proteome into four groups according to the target development level, i.”
BackgroundTCRD and pharos 2021: mining the human proteome for disease biology
Sheils, T. K., Mathias, S. L., Kelleher, K. J., Siramshetty, V. B., Nguyen, D.-T., Bologa, C. G., Jensen, L. J., Vidović, D., Koleti, A., Schürer, S. C., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa993 · Cited by 160
Research works printed but not linked: 41
- Young, D.C. (2009). Properties that make a molecule a good drug. Computational Drug Design, John Wiley & Sons, Inc. · doi:10.1002/9780470451854.ch2
- Rowland, M., and Tozer, T.N. (2011). Fundamental concepts and terminology. Clinical Pharmacokinetics and Pharmacodynamics, Lippincott Williams & Wilkins. [4th ed.].
- Sinha, S., and Vohora, D. (2018). Drug discovery and development: An overview. Pharmaceutical Medicine and Translational Clinical Research, Elsevier Inc. · DOI
- Doytchinova, 2018, Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database, J. Enzym. Inhib. Med. Chem., 33, 768, 10.1080/14756366.2018.1458031 · DOI
- Ban, 2006, The role of serendipity in drug discovery, Dialogues Clin. Neurosci., 8, 335, 10.31887/DCNS.2006.8.3/tban · DOI · Paper page
- Cheng, 2013, Hartmann Stahelin (1925–2011) and the contested history of cyclosporin A, Clin. Transplant., 27, 326, 10.1111/ctr.12072 · DOI
- Guo, 2017, The modification of natural products for medical use, Acta Pharm. Sin. B, 7, 119, 10.1016/j.apsb.2016.06.003 · DOI · Paper page
- Montinari, 2019, The first 3500 years of aspirin history from its roots—A concise summary, Vascul. Pharmacol., 113, 1, 10.1016/j.vph.2018.10.008 · DOI · Paper page
- Roberts, 1984, Clinical pharmacokinetics of ranitidine, Clin. Pharmacokinet., 9, 211, 10.2165/00003088-198409030-00003 · doi:10.2165/00003088-198409030-00003
- Meier, 1982, Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents, Am. Heart J., 104, 364, 10.1016/0002-8703(82)90127-2 · DOI
- Shoichet, 2004, Virtual screening of chemical libraries, Nature, 432, 862, 10.1038/nature03197 · DOI · Paper page
- Butkiewicz, 2017, High-throughput screening assay datasets from the PubChem database, Chem. Inform., 3, 1, 10.21767/2470-6973.100022 · DOI
- Smith, 2002, Screening for drug discovery: The leading question, Nature, 418, 453
- Bentley, 2009, Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams), J. Ind. Microbiol. Biotechnol., 36, 775, 10.1007/s10295-009-0553-8 · DOI
- Wall, 1995, Camptothecin and taxol: Discovery to clinic—Thirteenth Bruce F. Cain Memorial Award Lecture, Cancer Res., 55, 753
- Wilson, 2011, Integrating structure-based and ligand-based approaches for computational drug design, Future Med. Chem., 3, 735, 10.4155/fmc.11.18 · DOI · Paper page
- Berman, 2007, The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data, Nucleic Acids Res., 35, D301, 10.1093/nar/gkl971 · DOI · Paper page
- Novoa, 2021, A review on machine learning approaches and trends in drug discovery, Comput. Struct. Biotechnol. J., 19, 4538, 10.1016/j.csbj.2021.08.011 · DOI · Paper page
- Hansch, 1964, The use of substitutent constants in the analysis of the structure-activity relationship in penicillin derivatives, J. Med. Chem., 7, 691, 10.1021/jm00336a001 · DOI
- Martin, 2011, In tribute to Corwin Hansch, father of QSAR, J. Comput. Aided Mol. Des., 25, 491, 10.1007/s10822-011-9449-6 · doi:10.1007/s10822-011-9449-6
- Wold, 1983, Multivariate quantitative structure-activity relationships (QSAR): Conditions for their applicability, J. Chem. Inf. Comput. Sci., 23, 6, 10.1021/ci00037a002 · DOI · Paper page
- Wold, 1987, Multiway principal components and PLS-analysis, J. Chemometr., 1, 41, 10.1002/cem.1180010107 · DOI · Paper page
- Xu, 2002, Chemoinformatics and drug discovery, Molecules, 7, 566, 10.3390/70800566 · DOI · Paper page
- Mitchell, 2014, Machine learning methods in chemoinformatics, Wiley Interdiscip. Rev. Comput. Mol. Sci., 4, 468, 10.1002/wcms.1183 · DOI · Paper page
- Hessler, G., and Baringhaus, K.-H. (2018). Artificial Intelligence in Drug Design. Molecules, 23. · DOI · Paper page
- Duvaud, 2021, Expasy, the Swiss Bioinformatics Resource Portal, as designed by its users, Nucleic Acids Res., 49, W216, 10.1093/nar/gkab225 · DOI · Paper page
- Bragina, M.E., Daina, A., Perez, M.A.S., Michielin, O., and Zoete, V. (2022). SwissSimilarity 2021 web tool: Novel chemical libraries and additional methods for an enhanced ligand-based virtual screening experience. Int. J. Mol. Sci., 23. · DOI
- Cuizzo, 2022, SwissBioisostere 2021: Updated structural, bioactivity and physicochemical data delivered by a reshaped web interface, Nucleic Acids Res., 50, D1382, 10.1093/nar/gkab1047 · DOI
- Daina, 2019, SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules, Nucleic Acids Res., 47, W357, 10.1093/nar/gkz382 · DOI · Paper page
- Klucznik, 2018, Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory, Chem, 4, 522, 10.1016/j.chempr.2018.02.002 · DOI · Paper page
- MacKinnon, 2021, Proteome-scale drug-target interaction predictions: Approaches and applications, Curr. Protoc., 1, e302, 10.1002/cpz1.302 · DOI
- Zhong, 2018, Artificial intelligence in drug design, Sci. China Life Sci., 61, 1191, 10.1007/s11427-018-9342-2 · DOI · Paper page
- Grisoni, 2021, Artificial intelligence in drug discovery: Recent advances and future perspectives, Expert Opin. Drug Discov., 16, 949, 10.1080/17460441.2021.1909567 · DOI · Paper page
- Cavasotto, 2021, Artificial intelligence in the early stages of drug discovery, Arch. Biochem. Biophys., 698, 108730, 10.1016/j.abb.2020.108730 · DOI · Paper page
- Chan, 2019, Advancing drug discovery via artificial intelligence, Trends Pharmacol. Sci., 40, 592, 10.1016/j.tips.2019.06.004 · DOI · Paper page
- Zimmer, 1995, Bioorganic molecular mechanics, Chem. Rev., 95, 2629, 10.1021/cr00040a002 · doi:10.1021/cr00040a002
- Young, D.C. (2009). Molecular Mechanics. Computational Drug Design, John Wiley & Sons, Inc. · doi:10.1002/9780470451854.ch10
- Ganesan, 2017, Molecular dynamics-driven drug discovery: Leaping forward with confidence, Drug Discov. Today, 22, 249, 10.1016/j.drudis.2016.11.001 · DOI · Paper page
- Chen, 2009, Pharmacophore-based virtual screening versus docking-based virtual screening: A benchmark comparison against eight targets, Acta Pharmacol. Sin., 30, 1694, 10.1038/aps.2009.159 · DOI
- Muthas, 2008, Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering, J. Mol. Graph. Model., 26, 1237, 10.1016/j.jmgm.2007.11.005 · DOI
- Williams, 2015, Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases, J. R. Soc. Interface, 12, 20141289, 10.1098/rsif.2014.1289 · DOI · Paper page
Cited by
Intelligent Computing: The Latest Advances, Challenges, and Future
Zhu, S., Yu, T., Xu, T., Chen, H., Dustdar, S., Gigan, S., Gunduz, D., Hossain, E., Jin, Y., Lin, F., et al. (2023) · Intelligent Computing · doi:10.34133/icomputing.0006 · Cited by 290
A review of large language models and autonomous agents in chemistry
Ramos, M. C., Collison, C. J., & White, A. D. (2025) · Chemical Science · doi:10.1039/d4sc03921a · Cited by 274
FEP Protocol Builder: Optimization of Free Energy Perturbation Protocols Using Active Learning
de Oliveira, C., Leswing, K., Feng, S., Kanters, R., Abel, R., & Bhat, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00681 · Cited by 15
Metadata
- Authors
- Doytchinova, I.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-02-23
- Volume
- 27
- Issue
- 5
- Pages
- 1496
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4213438497
- Cited by
- 119
- References
- 16
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Science and Education for Smart Growth Operational Program (BG05M2OP001‐1.001‐0003)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.